2020 Year in Review - Biosimilars
2020 Year in Review - Biosimilars | January 13, 2021
Exploratory analyses of a phase 3 trial comparing adalimumab-afzb with reference adalimumab in patients with rheumatoid arthritis (RA) indicate a multibiomarker disease activity score may be a sensitive and objective assessment of biosimilarity that does not require subjective assessments needed for conventional disease activity measures.
2020 Year in Review - Biosimilars | January 13, 2021
Data from the ongoing PROPER study indicate switching from reference adalimumab to its biosimilar SB5 was not associated with any clinically meaningful difference in disease score from baseline in patients with rheumatoid arthritis (RA), axial spondyloarthritis, or psoriatic arthritis.
2020 Year in Review - Biosimilars | January 13, 2021
Longer-term follow-up supports earlier evidence that treatment switch from adalimumab-EU to PF-06410293 does not impact treatment safety, immunogenicity, and efficacy in patients with moderate-to-severe, active rheumatoid arthritis.
2020 Year in Review - Biosimilars | January 13, 2021
A randomized, double-blind phase 3 study demonstrated the efficacy and safety equivalence of the adalimumab biosimilar candidate CT-P17 to reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis (RA).
2020 Year in Review - Biosimilars | January 13, 2021
Real-world data from the prospective, observational COMPANION-B study showed that the biosimilar SB4 had similar efficacy over 12 months compared with etanercept reference in patients with well-controlled rheumatoid arthritis with stable disease.
2020 Year in Review - Biosimilars | January 13, 2021
The findings of a retrospective study indicate that successive switching from reference to 2 different biosimilars was not associated with clinically significant changes in disease activity and function in patients with inflammatory rheumatic diseases.
2020 Year in Review - Biosimilars | January 13, 2021
Preliminary real-world retrospective data indicate comparable safety profiles for infliximab-dyyb and infliximab in pediatric rheumatic conditions.
2020 Year in Review - Biosimilars | January 13, 2021
Exploratory analyses of a phase 3 trial comparing infliximab-qbtx to reference infliximab in patients with rheumatoid arthritis (RA) indicate that multibiomarker disease activity score may be used as an assessment of biosimilarity instead of conventional disease activity measures.
2020 Year in Review - Biosimilars | January 13, 2021
Interim results from the phase 3 TROIKA trial demonstrate clinical equivalence between the biosimilar HD201 and trastuzumab reference in terms of efficacy, safety, pharmacokinetics, and immunogenicity in patients with HER2-positive early breast cancer.
2020 Year in Review - Biosimilars | January 13, 2021
Real-world data indicate the efficacy and safety profile of the biosimilar trastuzumab-dttb + pertuzumab was consistent with that previously reported for trastuzumab reference + pertuzumab in patients with HER2-positive breast cancer.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512